CLEVELAND, Feb. 5 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), today announced that the Company was featured in an article in the February 5, 2007, issue of Barron's, in the This Week Preview section edited by Robin Goldwyn Blumenthal. The article, titled "(Free) Radical Idea, A Glowing Outlook?" may be accessed at: http://webreprints.djreprints.com/31956.html for 30 days. About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at http://www.cbiolabs.com/. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006. Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E: DATASOURCE: Cleveland BioLabs, Inc. CONTACT: Rachel Levine of The Global Consulting Group, +1-646-284-9439, or , for Cleveland BioLabs, Inc. Web site: http://www.cbiolabs.com/ http://webreprints.djreprints.com/31956.html

Copyright